EncephalitisSEAeNCT04089436
SouthEast Asia Encephalitis Project
An observational study of Encephalitis, run by Institut Pasteur at 7 sites in 4 countries.
Trial summary
Encephalitis, an acute inflammation of the central nervous system associated with neurologic dysfunction is of public health concern worldwide, because of its high mortality and neurological sequelae rates. In Asia where many of the possible etiologies are of major public health concerns (i.e. Read more about this study
- Who is it for?
- Ages 28 days and older
- Conditions the study is for
- Encephalitis
- What is being tested?
- CSF sampling, Blood sampling and Nasopharyngeal and rectal sampling
- Type of treatment
- Injection or infusion
- How many people
- 800 participants
- Where
- 7 sitesin 4 countries
- Study dates
- 15 Jul 2014to 31 Dec 2019
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 28 days and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with suspected encephalitis Hospitalized in 4 different Hospitals, Kantha Bopha IV children's Hospital, Phnom Penh, Cambodia, National paediatrics Hospital, Hanoi, Vietnam and Mahosot Hospital, Vientiane, Lao PDR, and Yangon Children Hospital, Yangon, Myanmar.
Who may be able to join
- presenting altered mental status (i.e. confusion or inability to talk, decreased or altered level of consciousness or personality change AND lasting 24 hours or more AND no alternative cause identified);
- AND at least one of minor inclusion criteria must be met before patient inclusion:
- presenting fever (38°C axillary) for less than 72 hours before or after presentation;
- seizure (febrile seizure excluded);
- focal neurologic finding.
Who cannot join
- None
Trial locations and contacts
7 sites in 4 countries.
7 sites in 4 countries
Cambodia2 sites
Institut Pasteur of Cambodia
Phnom Penh
Kantha Bopha IV children Hospital
Phnom Penh
Vietnam2 sites
National Hospital of Pediatrics
Hanoi
National Institute of Hygiene Epidemiology
Hanoi
About this study
Official title: The Threat of Infectious Encephalitis in Southeast Asia: SouthEast Asia Encephalitis Project
Encephalitis, an acute inflammation of the central nervous system associated with neurologic dysfunction is of public health concern worldwide, because of its high mortality and neurological sequelae rates. In Asia where many of the possible etiologies are of major public health concerns (i.e. dengue, Japanese encephalitis, West Nile virus, EV71), acute encephalitis is among the most frequent and severe causes of pediatric hospitalization.
Despite extensive microbiological investigations, no pathogen is identified for a significant proportion of encephalitis patients in both industrialized and developing countries (28-85% of cases remain unconfirmed). Unknown and sometimes new emerging infectious agents may be responsible for cases of currently unknown etiology and an intensive effort to identify and characterize them is to be done. From this perspective, the Southeast Asian region, a particularly significant biodiversity hotspot, is at high risk for new pathogen emergence.
Read more
Surveillance and diagnostic capabilities for encephalitis remain poor and still suffer from serious shortcomings in most Southeast Asian countries and beyond. Although the burden of non-infectious encephalitis in this region remains to be ascertained, the best laboratories only identify etiological infective agents in less than half of patients. Systematic data regarding the contribution of these diseases are lacking and to define the burden of these infections, to describe the full clinical spectrum and characteristics of acute central nervous system infections, and to develop diagnostic and therapeutic algorithms to improve patient care.
The proposed project is an ambitious and multidisciplinary research consortium that aims to reduce the morbidity and mortality associated with infectious encephalitis in Southeast Asia (Cambodia, Laos, Vietnam and Myanmar) by improving diagnosis and medical care for patients.
The SEAe project specific objectives are:
- To fill-in the biomedical knowledge gaps regarding acute encephalitis syndrome;
- To strengthen hospital laboratories capacities to enhance health by improving diagnosis and care for patients;
- To identify unknown pathogens responsible for encephalitis;
- To provide reliable information and a sustainable regional and sub-regional surveillance network to clinicians and public health stakeholders that will help them to better define prevention policies, vaccination strategy, and build preparedness to emerging infectious risks.
Read the detailed description
Background:
Encephalitis is defined as an acute inflammation of the central nervous system associated with neurologic dysfunction. The most common etiologies are infections by either viruses or bacteria although parasites and fungi can also be occasionally detected, especially in immunocompromised patients. Because of high mortality and long-term neurological sequelae, encephalitis is of public health concern worldwide. Reported incidences range between 3.5 and 7.4 cases per 100,000 patient-years with higher incidences in children than adults. Various encephalitis outbreaks have recently emerged in Asia such as the fatal outbreak of enterovirus 71 (EV71) that occurred in mid-2012 in Cambodia affecting very young children (most below 3 years, all below 12 years). In Asia where many of the possible etiologies are of major public health concerns (i.e. dengue, Japanese encephalitis, West Nile virus, EV71), acute encephalitis is among the most frequent and severe causes of pediatric hospitalization.
Despite extensive microbiological investigations and the use of the most advanced molecular biology-based assays, no pathogen is identified for a significant proportion of encephalitis patients in both industrialized and developing countries (28-85% of cases remain unconfirmed). Previous studies support the hypothesis that unknown and sometimes new emerging infectious agents may be responsible for cases of currently unknown etiology and strongly argue for an intensive effort to identify and characterize them. This hypothesis is also strengthened by the recent apparent increase in emerging infectious diseases, many of which have been linked to human activities that impact the environment and to the spreading of pathogens to new geographic regions. From this perspective, the Southeast Asian region, a particularly significant biodiversity hotspot, is at high risk for new pathogen emergence. Indeed, growing human populations, increasing urbanization and frequent contact with wildlife and domesticated animals have created novel opportunities for the emergence of pathogens such as SARS at the end of 2002, and highly facilitated the spread of infectious diseases such as H5N1 high-pathogenicity avian influenza virus since 2004, and H1N1 pandemic influenza virus in 2009. The population in developing Southeast Asian countries is particularly at risk for the circulation of emerging or reemerging infectious agents and for this reason the surveillance and investigation of acute encephalitis syndrome in this region is of utmost public health importance, both locally and globally.
Surveillance and diagnostic capabilities for encephalitis remain poor and still suffer from serious shortcomings in most Southeast Asian countries and beyond. Although the burden of non-infectious encephalitis in this region remains to be ascertained, the best laboratories only identify etiological infective agents in less than half of patients. Moreover, because of the absence of reliable microbiological diagnostic capacity in the majority of public referral hospitals, local clinicians have to treat acute encephalitis syndromes mostly empirically, with little evaluation of the effectiveness of their clinical approach. Even if some of the most common causes of acute encephalitis syndrome may be vaccine-preventable, systematic data regarding the contribution of these diseases are lacking and no reliable data are available to define the burden of these infections, to describe the full clinical spectrum and characteristics of acute central nervous system infections, and to develop diagnostic and therapeutic algorithms to improve patient care. Besides, whatever the nature and magnitude of the encephalitis burden in Southeast Asia and the criteria used to assess it (i.e. morbidity, mortality, handicap, impact on families' budget or livelihood), this burden is borne principally by underprivileged populations with limited access to prevention and health care.
Project partners The proposed project is an ambitious and multidisciplinary research consortium associating: (i) national health authorities in Cambodia, Lao PDR, Vietnam and Myanmar; (ii) local major university and clinical sites (national hospitals and provincial health centers); (iii) key French stakeholders of life and health sciences with research activities carried out in the Southeast Asian region such as: Institut Pasteur and the Institut Pasteur International Network, Institut National de la Santé et de la Recherche Médicale (Inserm), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad), Institut de Recherche pour le Développement (IRD) - Aix-Marseille University - Ecole des Hautes Etudes en Santé Publique (EHESP); and (iv) teams from the Southeast Asian Wellcome Trust Oxford University Major Overseas Programme.
Objectives:
The SEAe project aims to reduce the morbidity and mortality associated with infectious encephalitis in Southeast Asia by improving diagnosis and medical care for patients.
The SEAe project specific objectives are:
- To fill-in the biomedical knowledge gaps regarding acute encephalitis syndrome;
- To strengthen hospital laboratories capacities to enhance health by improving diagnosis and care for patients;
- To identify unknown pathogens responsible for encephalitis;
- To document and analyze factors related to clusters of encephalitis cases integrating human health, animal health and environment through a "One Health" approach;
- To provide reliable information and a sustainable regional and sub-regional surveillance network to clinicians and public health stakeholders that will help them to better define prevention policies, vaccination strategy, and build preparedness to emerging infectious risks.
Population study: patient with suspected encephalitis hospitalized in in 4 different Hospitals, Kantha Bopha IV children's Hospital, Phnom Penh, Cambodia, National paediatrics Hospital, Hanoi, Vietnam and Mahosot Hospital, Vientiane, Lao PDR, Yangon Children Hospital, Yangon, Myanmar. Inclusion criteria were adapted from the International Encephalitis Consortium 2013: all patients should be older than 28 days and presenting an altered mental status (i.e. confusion or inability to talk, decreased or altered level of consciousness or personality change) lasting more than 24 hours without alternative cause identified. These criteria should be associated with at least one of the following: (i) fever (>=38°C axillary) for less than 72 hours before or after presentation; (ii) seizure (febrile seizure excluded); (iii) focal neurologic finding.
Data collection:
Clinical data entries are required for this study.
Data entries:
A single data entry person (a medical doctor) enters clinical information and fill in a paper form at admission, at 24 hours, at discharge and one year after discharge and enter the data into an OpenClinica (hosted in CIRAD server, Montpellier, France ) anonymized online database.
Laboratory data is entered into a customized ACCESS (Microsoft database). The results are entered into dedicated tabs for the different techniques.
A data manager dedicated to the study is in charge of the database. The CIRAD and the Institut Pasteur share the co-ownership of the database.
First statistical analysis will be performed in Institut Pasteur du Cambodge, Phnom Penh, under epidemiology unit responsibility. Continuous data will be described with descriptive statistics, including mean ±SD and/or median (range) as appropriate and categorical data with frequencies (%). Categorical data will be analyzed by univariate analysis with χ2 or Fisher exact test as appropriate and continuous data by nonparametric Mann-Whitney test. Statistical analyses will involve use of R software. Relationships between clinical, biological, radiological variables, etiologies and outcome will be assessed by using a univariate and multivariate logistic regression analyses to identify determinants for poor outcome.
Study Calendar
- Provisional inclusion starting date: July 2014
- Provisional inclusion duration: 3 years and half
- Patient participation duration: 1 year
- Study provisional duration: 5 years
- Data archiving duration: 15 years
- Conditions
- Encephalitis
- Being tested
- CSF sampling, Blood sampling, Nasopharyngeal and rectal sampling
- Keywords
- Encephalitis, Southeast Asia, Japanese encephalitis, Next Generation sequencing
- Medical subject headings
- Encephalitis, Encephalitis, Japanese
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CSF samplingDiagnostic test
CSF sampling by lumbar puncture
Blood samplingDiagnostic test
Blood sampling by blood test
Nasopharyngeal and rectal samplingDiagnostic test
Nasopharyngeal and rectal sample by swabbing
| Study group | Role | What they receive |
|---|---|---|
| patients with encephalitis | children above 28days and adults with suspected encephalitis Hospitalized in 4 different Hospitals, Kantha Bopha IV children's Hospital, Phnom Penh, Cambodia, National paediatrics Hospital, Hanoi, Vietnam and Mahosot Hospital, Vientiane, Lao PDR, and Yangon Children Hospital, Yangon, Myanmar Receives: Diagnostic Test: CSF sampling; Diagnostic Test: Blood sampling; Diagnostic Test: Nasopharyngeal and rectal sampling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Identify etiologies of encephalitis in South East Asia (Vietnam, Laos, Cambodia and Myanmar).
Proportion of patients with confirmed or probable etiologies and proportion with unidentified pathogen
Measured: August 2019
Secondary outcomes (3)
Describe clinical and biological features of patients with encephalitis
Proportion of participants by demographic data (geographic origin, age), by clinical and biological features assessed by physician (general symptoms, neurological symptoms, length of symptoms, blood pressure, blood pulse, weight, height, white blood cells, platelets counts, hemoglobin, CSF cells, protein glucose levels).
Measured: August 2019
describe clinical outcomes of encephalitis in general and by etiology
Proportion of patient who died or had neurological sequelae or recovered during hospitalization and at one year
Measured: December 2019
Identify factors associated with death or severe neurological sequelea in patients with confirmed infectious encephalitis (survival analyses, sequelea score).
Estimation of risk ratio for death or severe neurological sequelae in patients with confirmed infectious encephalitis by demographic, clinical, and biological data
Measured: December 2019
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Sep 2019
- Study start15 Jul 2014
- Primary completion30 Sep 2019 (estimated)
- Study completion31 Dec 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for EncephalitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 800 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Institut Pasteur
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Centre De Coopération International En Recherche Agronomique Pour Le Développement, Institut National de la Santé Et de la Recherche Médicale, France, Institut Pasteur, Cambodia, Institut de Recherche pour le Developpement, National Institute of Hygiene and Epidemiology, Vietnam, University of Oxford, National Health Laboratory, Myanmar
- Responsible party
- Sponsor
- Investigators
- Marc LECUIT, MD, PhD, Principal investigator, Institut Pasteur
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04089436
- Sponsor's protocol ID
- 2013-024
- Acronym
- SEAe
- Status last verified
- Sep 2019
- First submitted
- 28 Jun 2019
- Last updated
- 25 Sep 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Pommier JD, Gorman C, Crabol Y, Bleakley K, Sothy H, Santy K, Tran HTT, Nguyen LV, Bunnakea E, Hlaing CS, Aye AMM, Cappelle J, Herrant M, Piola P, Rosset B, Chevalier V, Tarantola A, Channa M, Honnorat J, Pinto AL, Rattanavong S, Vongsouvath M, Mayxay M, Phangmanixay S, Phongsavath K, Tin OS, Kyaw LL, Tin HH, Linn K, Tran TMH, Perot P, Thuy NTT, Hien N, Phan PH, Buchy P, Dussart P, Laurent D, Eloit M, Dubot-Peres A, Lortholary O, de Lamballerie X, Newton PN, Lecuit M; SEAe Consortium. Childhood encephalitis in the Greater Mekong region (the SouthEast Asia Encephalitis Project): a multicentre prospective study. Lancet Glob Health. 2022 Jul;10(7):e989-e1002. doi: 10.1016/S2214-109X(22)00174-7.
PubMed 35714649
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Threat of Infectious Encephalitis in Southeast Asia: SouthEast Asia Encephalitis Project
- ClinicalTrials.gov ID
- NCT04089436
- Acronym / sponsor ID
- SEAe / 2013-024
- Conditions
- Encephalitis
- Keywords
- Encephalitis, Southeast Asia, Japanese encephalitis, Next Generation sequencing
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 800 participants (estimated)
- Lead sponsor
- Institut PasteurIndustry (pharma, biotech, devices)
- Collaborators
- Centre De Coopération International En Recherche Agronomique Pour Le Développement, Institut National de la Santé Et de la Recherche Médicale, France, Institut Pasteur, Cambodia, Institut de Recherche pour le Developpement, National Institute of Hygiene and Epidemiology, Vietnam, University of Oxford, National Health Laboratory, Myanmar
- Study start
- 15 Jul 2014 (actual)
- Primary completion
- 30 Sep 2019 (estimated)
- Study completion
- 31 Dec 2019 (estimated)
- First posted
- 13 Sep 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Encephalitis, an acute inflammation of the central nervous system associated with neurologic dysfunction is of public health concern worldwide, because of its high mortality and neurological sequelae rates. In Asia where many of the possible etiologies are of major public health concerns (i.e. dengue, Japanese encephalitis, West Nile virus, EV71), acute encephalitis is among the most frequent and severe causes of pediatric hospitalization.
Despite extensive microbiological investigations, no pathogen is identified for a significant proportion of encephalitis patients in both industrialized and developing countries (28-85% of cases remain unconfirmed). Unknown and sometimes new emerging infectious agents may be responsible for cases of currently unknown etiology and an intensive effort to identify and characterize them is to be done. From this perspective, the Southeast Asian region, a particularly significant biodiversity hotspot, is at high risk for new pathogen emergence.
Surveillance and diagnostic capabilities for encephalitis remain poor and still suffer from serious shortcomings in most Southeast Asian countries and beyond. Although the burden of non-infectious encephalitis in this region remains to be ascertained, the best laboratories only identify etiological infective agents in less than half of patients. Systematic data regarding the contribution of these diseases are lacking and to define the burden of these infections, to describe the full clinical spectrum and characteristics of acute central nervous system infections, and to develop diagnostic and therapeutic algorithms to improve patient care.
The proposed project is an ambitious and multidisciplinary research consortium that aims to reduce the morbidity and mortality associated with infectious encephalitis in Southeast Asia (Cambodia, Laos, Vietnam and Myanmar) by improving diagnosis and medical care for patients.
The SEAe project specific objectives are:
- To fill-in the biomedical knowledge gaps regarding acute encephalitis syndrome;
- To strengthen hospital laboratories capacities to enhance health by improving diagnosis and care for patients;
- To identify unknown pathogens responsible for encephalitis;
- To provide reliable information and a sustainable regional and sub-regional surveillance network to clinicians and public health stakeholders that will help them to better define prevention policies, vaccination strategy, and build preparedness to emerging infectious risks.
Detailed description
Background:
Encephalitis is defined as an acute inflammation of the central nervous system associated with neurologic dysfunction. The most common etiologies are infections by either viruses or bacteria although parasites and fungi can also be occasionally detected, especially in immunocompromised patients. Because of high mortality and long-term neurological sequelae, encephalitis is of public health concern worldwide. Reported incidences range between 3.5 and 7.4 cases per 100,000 patient-years with higher incidences in children than adults. Various encephalitis outbreaks have recently emerged in Asia such as the fatal outbreak of enterovirus 71 (EV71) that occurred in mid-2012 in Cambodia affecting very young children (most below 3 years, all below 12 years). In Asia where many of the possible etiologies are of major public health concerns (i.e. dengue, Japanese encephalitis, West Nile virus, EV71), acute encephalitis is among the most frequent and severe causes of pediatric hospitalization.
Despite extensive microbiological investigations and the use of the most advanced molecular biology-based assays, no pathogen is identified for a significant proportion of encephalitis patients in both industrialized and developing countries (28-85% of cases remain unconfirmed). Previous studies support the hypothesis that unknown and sometimes new emerging infectious agents may be responsible for cases of currently unknown etiology and strongly argue for an intensive effort to identify and characterize them. This hypothesis is also strengthened by the recent apparent increase in emerging infectious diseases, many of which have been linked to human activities that impact the environment and to the spreading of pathogens to new geographic regions. From this perspective, the Southeast Asian region, a particularly significant biodiversity hotspot, is at high risk for new pathogen emergence. Indeed, growing human populations, increasing urbanization and frequent contact with wildlife and domesticated animals have created novel opportunities for the emergence of pathogens such as SARS at the end of 2002, and highly facilitated the spread of infectious diseases such as H5N1 high-pathogenicity avian influenza virus since 2004, and H1N1 pandemic influenza virus in 2009. The population in developing Southeast Asian countries is particularly at risk for the circulation of emerging or reemerging infectious agents and for this reason the surveillance and investigation of acute encephalitis syndrome in this region is of utmost public health importance, both locally and globally.
Surveillance and diagnostic capabilities for encephalitis remain poor and still suffer from serious shortcomings in most Southeast Asian countries and beyond. Although the burden of non-infectious encephalitis in this region remains to be ascertained, the best laboratories only identify etiological infective agents in less than half of patients. Moreover, because of the absence of reliable microbiological diagnostic capacity in the majority of public referral hospitals, local clinicians have to treat acute encephalitis syndromes mostly empirically, with little evaluation of the effectiveness of their clinical approach. Even if some of the most common causes of acute encephalitis syndrome may be vaccine-preventable, systematic data regarding the contribution of these diseases are lacking and no reliable data are available to define the burden of these infections, to describe the full clinical spectrum and characteristics of acute central nervous system infections, and to develop diagnostic and therapeutic algorithms to improve patient care. Besides, whatever the nature and magnitude of the encephalitis burden in Southeast Asia and the criteria used to assess it (i.e. morbidity, mortality, handicap, impact on families' budget or livelihood), this burden is borne principally by underprivileged populations with limited access to prevention and health care.
Project partners The proposed project is an ambitious and multidisciplinary research consortium associating: (i) national health authorities in Cambodia, Lao PDR, Vietnam and Myanmar; (ii) local major university and clinical sites (national hospitals and provincial health centers); (iii) key French stakeholders of life and health sciences with research activities carried out in the Southeast Asian region such as: Institut Pasteur and the Institut Pasteur International Network, Institut National de la Santé et de la Recherche Médicale (Inserm), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad), Institut de Recherche pour le Développement (IRD) - Aix-Marseille University - Ecole des Hautes Etudes en Santé Publique (EHESP); and (iv) teams from the Southeast Asian Wellcome Trust Oxford University Major Overseas Programme.
Objectives:
The SEAe project aims to reduce the morbidity and mortality associated with infectious encephalitis in Southeast Asia by improving diagnosis and medical care for patients.
The SEAe project specific objectives are:
- To fill-in the biomedical knowledge gaps regarding acute encephalitis syndrome;
- To strengthen hospital laboratories capacities to enhance health by improving diagnosis and care for patients;
- To identify unknown pathogens responsible for encephalitis;
- To document and analyze factors related to clusters of encephalitis cases integrating human health, animal health and environment through a "One Health" approach;
- To provide reliable information and a sustainable regional and sub-regional surveillance network to clinicians and public health stakeholders that will help them to better define prevention policies, vaccination strategy, and build preparedness to emerging infectious risks.
Population study: patient with suspected encephalitis hospitalized in in 4 different Hospitals, Kantha Bopha IV children's Hospital, Phnom Penh, Cambodia, National paediatrics Hospital, Hanoi, Vietnam and Mahosot Hospital, Vientiane, Lao PDR, Yangon Children Hospital, Yangon, Myanmar. Inclusion criteria were adapted from the International Encephalitis Consortium 2013: all patients should be older than 28 days and presenting an altered mental status (i.e. confusion or inability to talk, decreased or altered level of consciousness or personality change) lasting more than 24 hours without alternative cause identified. These criteria should be associated with at least one of the following: (i) fever (>=38°C axillary) for less than 72 hours before or after presentation; (ii) seizure (febrile seizure excluded); (iii) focal neurologic finding.
Data collection:
Clinical data entries are required for this study.
Data entries:
A single data entry person (a medical doctor) enters clinical information and fill in a paper form at admission, at 24 hours, at discharge and one year after discharge and enter the data into an OpenClinica (hosted in CIRAD server, Montpellier, France ) anonymized online database.
Laboratory data is entered into a customized ACCESS (Microsoft database). The results are entered into dedicated tabs for the different techniques.
A data manager dedicated to the study is in charge of the database. The CIRAD and the Institut Pasteur share the co-ownership of the database.
First statistical analysis will be performed in Institut Pasteur du Cambodge, Phnom Penh, under epidemiology unit responsibility. Continuous data will be described with descriptive statistics, including mean ±SD and/or median (range) as appropriate and categorical data with frequencies (%). Categorical data will be analyzed by univariate analysis with χ2 or Fisher exact test as appropriate and continuous data by nonparametric Mann-Whitney test. Statistical analyses will involve use of R software. Relationships between clinical, biological, radiological variables, etiologies and outcome will be assessed by using a univariate and multivariate logistic regression analyses to identify determinants for poor outcome.
Study Calendar
- Provisional inclusion starting date: July 2014
- Provisional inclusion duration: 3 years and half
- Patient participation duration: 1 year
- Study provisional duration: 5 years
- Data archiving duration: 15 years
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Year
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| patients with encephalitis | – | Diagnostic Test: CSF sampling, Diagnostic Test: Blood sampling, Diagnostic Test: Nasopharyngeal and rectal samplingchildren above 28days and adults with suspected encephalitis Hospitalized in 4 different Hospitals, Kantha Bopha IV children's Hospital, Phnom Penh, Cambodia, National paediatrics Hospital, Hanoi, Vietnam and Mahosot Hospital, Vientiane, Lao PDR, and Yangon Children Hospital, Yangon, Myanmar |
Who may qualify
- Ages
- 28 days and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with suspected encephalitis Hospitalized in 4 different Hospitals, Kantha Bopha IV children's Hospital, Phnom Penh, Cambodia, National paediatrics Hospital, Hanoi, Vietnam and Mahosot Hospital, Vientiane, Lao PDR, and Yangon Children Hospital, Yangon, Myanmar.
Key inclusion criteria (5 listed)
- presenting altered mental status (i.e. confusion or inability to talk, decreased or altered level of consciousness or personality change AND lasting 24 hours or more AND no alternative cause identified);
- presenting fever (38°C axillary) for less than 72 hours before or after presentation;
- seizure (febrile seizure excluded);
- focal neurologic finding.
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CSF samplingCSF sampling by lumbar puncture | Diagnostic test | patients with encephalitis |
| Blood samplingBlood sampling by blood test | Diagnostic test | patients with encephalitis |
| Nasopharyngeal and rectal samplingNasopharyngeal and rectal sample by swabbing | Diagnostic test | patients with encephalitis |
Primary outcome
Identify etiologies of encephalitis in South East Asia (Vietnam, Laos, Cambodia and Myanmar).
Time frame: August 2019
Proportion of patients with confirmed or probable etiologies and proportion with unidentified pathogen
3 secondary outcomes
Describe clinical and biological features of patients with encephalitis
Time frame: August 2019
describe clinical outcomes of encephalitis in general and by etiology
Time frame: December 2019
Identify factors associated with death or severe neurological sequelea in patients with confirmed infectious encephalitis (survival analyses, sequelea score).
Time frame: December 2019
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2019.
- Derived from this study: PubMed 35714649Pommier JD, Gorman C, Crabol Y, Bleakley K, Sothy H, Santy K, Tran HTT, Nguyen LV, Bunnakea E, Hlaing CS, Aye AMM, Cappelle J, Herrant M, Piola P, Rosset B, Chevalier V, Tarantola A, Channa M, Honnorat J, Pinto AL, Rattanavong S, Vongsouvath M, Mayxay M, Phangmanixay S, Phongsavath K, Tin OS, Kyaw LL, Tin HH, Linn K, Tran TMH, Perot P, Thuy NTT, Hien N, Phan PH, Buchy P, Dussart P, Laurent D, Eloit M, Dubot-Peres A, Lortholary O, de Lamballerie X, Newton PN, Lecuit M; SEAe Consortium. Childhood encephalitis in the Greater Mekong region (the SouthEast Asia Encephalitis Project): a multicentre prospective study. Lancet Glob Health. 2022 Jul;10(7):e989-e1002. doi: 10.1016/S2214-109X(22)00174-7.
- Individual participant dataSharing planned: No
Related trials for Encephalitis
Not yet recruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
RecruitingObservational study
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
Progressive Multifocal Leukoencephalopathy
Recruiting
OPM- MEG in Non-immune And iMmune-medIated Neurological Disease
Autoimmune Encephalitis (AE), Acute Disseminated Encephalomyelitis
Not yet recruitingPhase 1/2
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica
RecruitingPhase 2
T-cell Therapy in Patients With PML
Progressive Multifocal Leucoencephalopathy (PML)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Marc LECUIT, MD, PhD principal investigator
Institut Pasteur
7 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Encephalitis, run by Institut Pasteur at 7 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in Burma, Cambodia, Vietnam, Laos. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Identify etiologies of encephalitis in South East Asia (Vietnam, Laos, Cambodia and Myanmar). (time frame: August 2019). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04089436, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2019.